Amendment: SEC Form S-4/A filed by GlycoMimetics Inc.
$GLYC
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/21/2025 | Overweight | Cantor Fitzgerald | |
| 7/26/2024 | Buy → Hold | TD Cowen | |
| 12/22/2023 | $12.00 | Overweight | CapitalOne |
| 11/12/2021 | $3.00 → $4.00 | Hold → Buy | Jefferies |
4 - GLYCOMIMETICS INC (0001253689) (Issuer)
4 - GLYCOMIMETICS INC (0001253689) (Issuer)
4 - GLYCOMIMETICS INC (0001253689) (Issuer)
SC 13G - GLYCOMIMETICS INC (0001253689) (Subject)
SC 13G/A - GLYCOMIMETICS INC (0001253689) (Subject)
SC 13G - GLYCOMIMETICS INC (0001253689) (Subject)
Cantor Fitzgerald initiated coverage of GlycoMimetics with a rating of Overweight
TD Cowen downgraded GlycoMimetics from Buy to Hold
CapitalOne initiated coverage of GlycoMimetics with a rating of Overweight and set a new price target of $12.00
Industry Veteran Brings 30 Years of Experience in Finance, Strategy and Operations WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent"), a private biotechnology company developing novel precision-engineered molecules targeting validated biology to advance care for patients with solid tumors, today announced the appointment of David Lubner to its board of directors. "David brings extensive experience in senior executive and board roles with particular expertise in finance, operations and corporate strategy," said Peter Harwin, chairman of Crescent's Board of Directors. "His contributions to Crescent will be instrumental as we continue to grow, advance
Jonathan McNeill, M.D., Appointed President and Chief Operating Officer Ellie Im, M.D., Appointed Chief Medical Officer Additional Leadership Appointments: Rick Scalzo, MBA, as Chief Financial Officer, and Amy Reilly, as Chief Communications Officer Team Brings Deep Experience in Oncology Drug Development, Clinical Operations and Building Biotechnology Companies Lead Program CR-001, an Intentionally Designed Tetravalent PD-1 x VEGF Bispecific Antibody, on Track for IND Submission in Fourth Quarter of 2025; Company Advancing Pipeline of Novel ADCs WALTHAM, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent"), a private biotechnology company developing novel p
WALTHAM, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent"), a private biotechnology company dedicated to advancing novel precision engineered molecules targeting validated biology to advance care for patients with solid tumors, announced management will present at the TD Cowen 45th Annual Health Care Conference on March 5, 2025, at 9:10 am ET. A live webcast of the presentation will be available at https://wsw.com/webcast/cowen177/cresc/2175696. An archived recording will be available for 90 days following the event. In October 2024, Crescent entered into an acquisition agreement with Rockville, Maryland-based GlycoMimetics, Inc. (NASDAQ:GLYC). Following
Following closing, the combined company will advance Crescent's portfolio of precision-engineered biologics to improve outcomes for patients with solid tumors Crescent's lead program CR-001, a tetravalent PD-1 x VEGF bispecific antibody incorporating the cooperative binding mechanism underpinning recent immuno-oncology breakthrough, expected to have preliminary proof of concept data in 2H26 Crescent pipeline also includes two novel antibody-drug conjugates with topoisomerase inhibitor payloads, CR-002 and CR-003 Concurrent financing of approximately $200 million anticipated to fund operations through 2027 Companies to hold a conference call on Tuesday October 29, at 8:00am EDT GlycoMim
Company exploring path forward for uproleselan in multiple AML settings based on observed efficacy results, including clinically meaningful results in primary refractory AML, and significant unmet patient need Uproleselan demonstrated a clinically meaningful improvement in median overall survival (mOS) for patients with primary refractory AML; mOS was 31.2 months for the uproleselan arm compared to 10.1 months for the placebo arm in this subgroup Adverse events for uproleselan were consistent with known side effect profiles of chemotherapy used in the study Advancing discussions with the National Cancer Institute (NCI) and the Alliance for Clinical Trials in Oncology for Phase 2/3
Study of uproleselan combined with chemotherapy did not meet its primary endpoint of overall survival in the intent to treat population Adverse events were consistent with known side effect profiles of chemotherapy used in the study Comprehensive data analysis with medical, statistical, and regulatory experts underway and will be shared as appropriate; company will submit results for presentation at an upcoming medical meeting National Cancer Institute (NCI) Phase 2/3 study in newly diagnosed AML patients remains ongoing Conference call and webcast to be hosted today, May 6, 2024, at 8:30 a.m. ET. GlycoMimetics, Inc. (NASDAQ:GLYC), a late clinical-stage biotechnology company
Industry Veteran Brings 30 Years of Experience in Finance, Strategy and Operations WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent"), a private biotechnology company developing novel precision-engineered molecules targeting validated biology to advance care for patients with solid tumors, today announced the appointment of David Lubner to its board of directors. "David brings extensive experience in senior executive and board roles with particular expertise in finance, operations and corporate strategy," said Peter Harwin, chairman of Crescent's Board of Directors. "His contributions to Crescent will be instrumental as we continue to grow, advance
GlycoMimetics, Inc. (NASDAQ:GLYC), a clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that Edwin Rock, M.D., Ph.D. has joined the executive leadership team as Chief Medical Officer (CMO). Dr. Rock brings nearly two decades of biopharmaceutical clinical development experience, most recently serving as CMO for Partner Therapeutics, a privately-held commercial stage biotech based in Massachusetts. "We are thrilled to have Ed join the GlycoMimetics team. His proven biopharmaceutical leadership in the development and commercialization of novel hematologic therapies will be a significant asset as w
GlycoMimetics, Inc. (NASDAQ:GLYC) announced today that Dr. Deepak Tiwari has joined the Company as Vice President, Technical Operations. "Dr. Tiwari brings over 25 years of diverse CMC experience. He has contributed to more than 30 regulatory submissions and 15 commercial product launches throughout his career. As we continue to move uproleselan forward, Deepak's breadth of experience and leadership is a valuable addition to GlycoMimetics," commented Harout Semerjian, GlycoMimetics' Chief Executive Officer. Dr. Tiwari joins the Company from Rafael Pharmaceuticals where he was Vice President and Head of CMC Operations working on development of devimistat in multiple indications including p
S-4/A - GLYCOMIMETICS INC (0001253689) (Filer)
425 - GLYCOMIMETICS INC (0001253689) (Subject)
8-K - GLYCOMIMETICS INC (0001253689) (Filer)
Recently, on June 20, 2024, an insider purchase was made at GlycoMimetics Inc., grabbing the attention of investors. According to the SEC Form 4 filing, SVP Finance, CFO Hahn Brian M. bought $4,335 worth of shares (17,500 units at $0.25), boosting direct ownership by 33% to 70,643 units. Insider transactions are closely monitored by investors as they can provide insights into the company's prospects and the confidence of insiders in the business. Let's delve deeper into the recent insider purchase and analyze any potential patterns or significance in comparison to other insider transactions at GlycoMimetics Inc. In early April 2024, Goldberg Mark Alan was granted 4,584 shares, augmenting di
4 - GLYCOMIMETICS INC (0001253689) (Issuer)
4 - GLYCOMIMETICS INC (0001253689) (Issuer)
4 - GLYCOMIMETICS INC (0001253689) (Issuer)